NYSE · SYK

Stryker Corporation

$330.25 +$11.28 (+3.54%) 1D After hours
Session Pulse Overnight session 1 mentions on Wed · 1 bullish / 0 bearish tags No new SEC filings since Mon close its sector ranked 6/11 this week Full pulse →
Charting by TradingView

Key Metrics

$122.28B
Market cap
36.64×
P/E · TTM
$25.27B
Revenue · TTM
$3.34B
Net income
EPS · TTM $8.64
Dividend yield 1.1%
Free cash flow $4.57B
Beta · 1Y 0.22
EBITDA · TTM $6.21B
Gross margin 63.8%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 11
    From its Feb 27 high, the share price fell 27%.

    Peak close $387.46 on Feb 27; trough close $282.58 on May 11. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -27%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$122.28B
Enterprise value$134.04B
Shares outstanding383.4M
52-wk range$281.00 – $404.14
Avg volume · 20D1.4M
Net cash −$11.76B
Book value / share$59.47
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNYSE
About Stryker Corporation
IPO dateMay 2, 1979
Employees56000

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E36.64
P/S4.84
P/FCF26.75
EV/EBITDA21.60
EV/Sales5.30
Graham №$107.50

Profitability

Gross 63.8%
Operating 18.2%
Net 13.2%
FCF 18.1%
ROE / ROIC 15.3% · 9.6%

Financial Health

Current ratio2.11
Quick ratio1.25
Debt / equity0.64
Debt / EBITDA 2.37
Net cash −$11.76B
Working capital$7.02B

Cash Flow · TTM

Operating CF $5.38B
Capex −$804.00M
Free cash flow $4.57B
Buybacks —
Dividends paid $1.30B
Shareholder yield 1.1%

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

4.8
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$107.50 vs $330.25
Trades 3.1× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings